Current disease modifying approaches to treat Parkinson's disease.
about
c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's DiseaseEstablished patterns of animal study design undermine translation of disease-modifying therapies for Parkinson's diseaseRecent advances in applying mass spectrometry and systems biology to determine brain dynamics.Segmental Aging Underlies the Development of a Parkinson Phenotype in the AS/AGU Rat.The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.An analysis of the rewarding and aversive associative properties of nicotine in the neonatal quinpirole model: Effects on glial cell line-derived neurotrophic factor (GDNF).l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?Non-human primate models of PD to test novel therapies.Commentary: Evaluation of Models of Parkinson's Disease.ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease.Commentary: A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease.Updates on immunity and inflammation in Parkinson disease pathology.Insight into the Dissociation of Behavior from Histology in Synucleinopathies and in Related Neurodegenerative Diseases.Iron Oxide Nanoparticle Delivery of Peptides to the Brain: Reversal of Anxiety during Drug Withdrawal.TNF superfamily member APRIL enhances midbrain dopaminergic axon growth and contributes to the nigrostriatal projection in vivo.Association between cerebral dopamine neurotrophic factor (CDNF) 2 polymorphisms and schizophrenia susceptibility and symptoms in the Han Chinese population.Neurturin overexpression in dopaminergic neurons induces presynaptic and postsynaptic structural changes in rats with chronic 6-hydroxydopamine lesion.Simultaneous Transplantation of Fetal Ventral Mesencephalic Tissue and Encapsulated Genetically Modified Cells Releasing GDNF in a Hemi-Parkinsonian Rat Model of Parkinson's Disease.Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease.Capsaicin Protects Against Oxidative Insults and Alleviates Behavioral Deficits in Rats with 6-OHDA-Induced Parkinson's Disease via Activation of TRPV1.Role of the microtubule-associated TPPP/p25 in Parkinson's and related diseases and its therapeutic potential.Neurotoxins as Preclinical Models for Parkinson's Disease.Parkinson's disease: towards better preclinical models and personalized treatments.Cerebral dopamine neurotrophic factor protects H9c2 cardiomyocytes from apoptosis.Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease.Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.Bioactivity-Guided Isolation of Neuritogenic Factor from the Seeds of the Gac Plant (Momordica cochinchinensis).Antioxidative CXXC Peptide Motif From Mesencephalic Astrocyte-Derived Neurotrophic Factor Antagonizes Programmed Cell DeathCombination of cell transplantation and glial cell line-derived neurotrophic factor-secreting encapsulated cells in Parkinson's disease
P2860
Q28070292-2211D9C2-57D0-46A5-9E82-2287FD613FD9Q36275707-63F0C764-D4EC-48EE-999C-41CC547E3DC9Q36379339-3C7C2429-A892-479F-B9E6-B74E630DD3DEQ37533588-3A4EA252-0944-4B93-BF5C-9FA6100DB2E8Q38670012-DF7B1292-D7A7-4EA6-AC86-ED114505529BQ38711758-25D62663-87FA-4EC0-B9B2-D5FCB92A9ABFQ39012371-17CDA256-D477-4AAB-9FEB-FBCBBF6AAD29Q39229450-23694EFA-E23D-46BF-AEC8-8BE1577A3282Q40307796-29A5A950-65A2-44E8-B82F-28D082157860Q41824342-7BA6AF03-3B69-43AC-9256-F1858299F652Q42490819-A6CF5F78-6517-4F4A-B6C2-F412FAEAAF0EQ42615002-07F20031-84DD-4DA9-88A8-048E255BAC17Q46132067-353D393E-7674-44E4-8101-7BA33E8BBF70Q46571207-DD9646B8-578C-4E02-8E4C-35DEB08D4BF0Q47110352-14C85035-EC8A-4B66-82A2-8AA34ED72554Q47138321-0D232E5A-5B3E-4666-9F74-4A1CA0C1741EQ47141045-88608048-28CA-4B72-BE2E-F9AF6009E783Q47162932-ED7ACC5C-81BA-40AC-8A99-3598B62EC8B7Q47234370-7697174E-8C1C-4100-914F-81ADE8A0553DQ47267653-57BFF8FC-F779-40C0-9655-A14FF2B81649Q48131059-D2906758-5130-4039-84EA-E8121F079153Q48274208-17921D69-CCF6-46EE-BFB7-F002CF215F89Q48291354-ED2A0CEA-246F-42D4-B9B6-E51BA11602B2Q50536122-663DB4D8-7000-4DA1-A598-46D34FDC1169Q51034617-676463E8-9946-4802-B7C4-08217DB07EC6Q52592689-4863B29A-B895-4CD6-95CF-9BEB4FEDB92DQ52658932-E6454BA2-68CE-4E67-A918-0E08B33D042CQ55465960-10BBD87F-77B7-4B66-9446-9DC8F5936739Q58764669-F374803D-BE21-4831-95CD-42DB1F4DBA07Q59137582-254772FA-2342-41C1-BE29-6576CDB90707
P2860
Current disease modifying approaches to treat Parkinson's disease.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Current disease modifying approaches to treat Parkinson's disease.
@en
type
label
Current disease modifying approaches to treat Parkinson's disease.
@en
prefLabel
Current disease modifying approaches to treat Parkinson's disease.
@en
P2093
P2860
P1476
Current disease modifying approaches to treat Parkinson's disease.
@en
P2093
Dan Lindholm
Giuseppa Mudò
Johanna Mäkelä
Mart Saarma
Natale Belluardo
Ove Eriksson
P2860
P2888
P304
P356
10.1007/S00018-015-2101-1
P577
2015-11-30T00:00:00Z